报价延迟最少15分钟:2025/07/20 13:09 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
37.23 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.29/-5.57
|
|
企业价值
5.40B
|
| 资产负债 |
|
每股账面净值
-2.23
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
18.47M
|
|
每股收益
0.07
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 13:09 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |
